Company news

Praxis Precision Medicines, Inc. news in 2026

Praxis Precision Medicines, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

October 27, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

July 30, 2026

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

July 6, 2026

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

June 29, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

June 21, 2026

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Praxis Precision Medicines Provides Vormatrigine Program Update

June 1, 2026

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

May 4, 2026

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

April 13, 2026

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

April 13, 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

April 5, 2026

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

March 29, 2026

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

February 19, 2026

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

February 9, 2026

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

February 2, 2026

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

January 13, 2026

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

January 11, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2026

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

January 8, 2026

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

January 6, 2026

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

January 5, 2026

Calls in 2026

Decks in 2026